参考文献：

[1]. Vuong J T,Stein-Merlob A F, Nayeri A, et al. Immune Checkpoint Therapies andAtherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-ArtReview[J]. Journal of the American College of Cardiology, 2022, 79(6): 577-593.

[2]. Drobni Z D, AlviR M, Taron J, et al. Association between immune checkpoint inhibitors withcardiovascular events and atherosclerotic plaque[J]. Circulation, 2020,142(24): 2299-2311.

[3]. Zhou M, Wang H,Zeng X, et al. Mortality, morbidity, and risk factors in China and itsprovinces, 1990–2017: a systematic analysis for the Global Burden of DiseaseStudy 2017[J]. The Lancet, 2019, 394(10204): 1145-1158.

[4]. Gotsman I,Grabie N, Dacosta R, et al. Proatherogenic immune responses are regulated bythe PD-1/PD-L pathway in mice[J]. The Journal of clinical investigation, 2007,117(10): 2974-2982.

[5]. Bu D, Tarrio M,Maganto-Garcia E, et al. Impairment of the programmed cell death-1 pathwayincreases atherosclerotic lesion development and inflammation[J]. Arteriosclerosis,thrombosis, and vascular biology, 2011, 31(5): 1100-1107.

[6]. Ewing M M,Karper J C, Abdul S, et al. T-cell co-stimulation by CD28–CD80/86 and itsnegative regulator CTLA-4 strongly influence accelerated atherosclerosisdevelopment[J]. International journal of cardiology, 2013, 168(3): 1965-1974.

[7]. Matsumoto T,Sasaki N, Yamashita T, et al. Overexpression of cytotoxicT-lymphocyte–associated antigen-4 prevents atherosclerosis in mice[J].Arteriosclerosis, thrombosis, and vascular biology, 2016, 36(6): 1141-1151.

[8]. Omori M, OkumaY, Hakozaki T, et al. Statins improve survival in patients previously treatedwith nivolumab for advanced non?small cell lung cancer: An observationalstudy[J]. Molecular and clinical oncology, 2019, 10(1): 137-143.

[9]. Cantini L, PecciF, Hurkmans D P, et al. High-intensity statins are associated with improvedclinical activity of PD-1 inhibitors in malignant pleural mesothelioma andadvanced non-small cell lung cancer patients[J]. European journal of cancer,2021, 144: 41-48.

[10]. Bird L. Statinsas adjuvants[J]. Nature Reviews Immunology, 2018, 18(11): 669-669.

[11]. Drobni Z D,Murphy S P, Alvi R M, et al. Association between incidental statin use andskeletal myopathies in patients treated with immune checkpoint inhibitors[J].Immunotherapy advances, 2021, 1(1): ltab014.

    以上就是本篇文章【免疫治疗副作用又有新花样： 不可小视的动脉粥样硬化, 应该怎样预防？】的全部内容了，欢迎阅览 ！ 文章地址：http://www.uqian.cn/quote/5020.html 
     行业      资讯      企业新闻      行情      企业黄页      同类资讯      网站地图      返回首页 极顶速云移动站 http://m.uqian.cn/ , 查看更多